Haematopoietic stem and progenitor cells (HSPC) mobilization, using cytokine-alone, is a well-tolerated regimen with predictable mobilization kinetics. Single-dose pegfilgrastim mobilizes HSPC efficiently; however, there is surprisingly little comparative data on its use without chemotherapy for HSPC mobilization. Pegfilgrastim-alone and filgrastim-alone mobilization regimens were compared in 52 patients with haematological malignancy. Pegfilgrastim 12 mg (n ¼ 20) or 6 mg (n ¼ 2) was administered Day 1 (D1) in 22 patients (lymphoma n ¼ 17; myeloma n ¼ 5). Thirty historical controls (lymphoma n ¼ 18; myeloma n ¼ 12) received filgrastim 10 mcg/kg daily from D1. Peripheral blood (PB) CD34 þ counts reached threshold (X5 Â 10 6 /L) and apheresis commenced on D4(4-5) and D4(4-6). Median PB CD34
INTRODUCTION
The emergence of recombinant human cytokines for the mobilization of haematopoietic stem and progenitor cells (HSPC) is one of the critical milestones in the history of haematopoietic SCT. The isolation and purification of G-CSF (filgrastim) and the discovery of its potent effect in mobilizing stem and progenitor cells into the PB has provided an alternative to harvesting BM as a source of HSPC for transplantation. Indeed, transplantation using mobilized PB HSPC has been found to result in superior engraftment rates than BM-derived HSPC for transplantation, especially with respect to platelet recovery.
1,2 HSPC mobilization is routinely achieved either using cytokine-alone or cytokine following myelosuppressive chemotherapy (chemo-cytokine mobilization).
Chemo-cytokine mobilization results in superior HSPC yields overall, [3] [4] [5] however there is increasing interest in outpatient-based cytokine-only regimens for mobilization owing to the improved acceptability to patients, the absence of risk of neutropenic complications and possibly more predictable mobilization kinetics compared with chemo-cytokine mobilization. In chemo-cytokine mobilization, the cytokine effect of filgrastim makes use of the wave of immature granulocytes that appear in the BM in the early phases of recovery after myelosuppressive chemotherapy. 6 In response to filgrastim receptor stimulation, these granulocytes liberate active neutrophil proteases that cleave the bonds between the HSPC and their microenvironment. 7 Filgrastim also mobilizes HSPC via other pathways, including the SDF-1 pathway that is currently a topic of interest in emerging therapies for stem cell mobilization, [8] [9] [10] such as AMD3100 (plerixafor) and others. [11] [12] [13] HSPC mobilization has traditionally been achieved with filgrastim at doses ranging from 5-30 mcg/kg daily, given either once daily or in a split dose. The most common mobilizing dose of filgrastim currently employed is 10 mcg/kg daily, which usually induces CD34 þ cell mobilization after B4 days of injections. This necessitates a minimum of 4, and up to 10 injections if daily filgrastim is used.
Pegylated filgrastim (pegfilgrastim) was developed to prolong the plasma half-life of filgrastim from 3-4 h to 33 h, by inhibiting its renal excretion, cellular uptake and proteolysis. 14, 15 Pegfilgrastim is currently marketed and approved for the prevention of chemotherapy-induced neutropenia and requires a single administration the day following chemotherapy. 14, 16, 17 Indeed, it is this long plasma half-life and single administration that also makes it an attractive agent to examine for HSPC mobilization.
Pegfilgrastim has been noted to efficiently mobilize HSPC in healthy volunteers, with PBCD34 þ counts peaking approximately day 4 post injection, at various doses. 14 Numerous groups later published equivalent mobilization efficiency between a single injection of 6 mg or 12 mg pegfilgrastim compared with multiple daily doses of filgrastim when these agents are used after mobilizing chemotherapy. [18] [19] [20] When used following chemotherapy for mobilization, pegfilgrastim levels may fall slightly as marrow recovery after myelosuppression causes an increase in the numbers of immature myeloid cells bearing G-CSF receptors, thus 'consuming' available pegfilgrastim. One report of pegfilgrastim plus mobilizing chemotherapy, in heavily treated patients with myeloma and lymphoma, demonstrated that B25% of patients may experience a dip in CD34 þ mobilization as neutrophil recovery occurs; 21 an effect that could be abrogated by providing a 'booster' dose of regular filgrastim at that time. Another group reported superior efficacy to filgrastim plus chemotherapy mobilization when two doses of pegfilgrastim were administered, at day þ 6 and day þ 13 post aggressive salvage chemotherapy in multiple myeloma. 22 In aggressive lymphoma post ESHAP (etoposide, methylprednisolone, cytarabine and cisplatin) chemotherapy pegfilgrastim 6 mg has demonstrated similar mobilization efficacy to a control group mobilized with filgrastim post ESHAP. 23 The adverse event profile of pegfilgrastim mobilization is very similar to filgrastim mobilization, including bone pain, skin reaction and rare reports of splenic rupture. [24] [25] [26] [27] Furthermore, earlier neutrophil recovery post chemotherapy and earlier timing of commencement of leukapheresis by B2 days was noted in patients transplanted with pegfilgrastim-mobilized HSPC. 28 Less has been published regarding the use of pegfilgrastim without chemotherapy for HSPC mobilization. Data comparing pegfilgrastim mobilization to filgrastim-alone mobilization is particularly scarce, with five published reports [29] [30] [31] [32] [33] and one unpublished trial by Amgen in 2005; only two of the published reports are in autologous adult mobilization, 31, 32 neither of which is a truly comparative study. In this retrospective analysis, we present data comparing pegfilgrastim versus filgrastim in terms of mobilization kinetics and efficiency in 52 patients with haematological malignancy undergoing cytokine-only mobilization.
PATIENTS AND METHODS Patients
Between January 2007 and October 2009, a total of 52 patients were mobilized with cytokine-alone at our institution. Pegfilgrastim was used in 22 patients, and filgrastim was used in 30 patients. At our institution, the choice of a cytokine-alone mobilizing regimen (as opposed to a chemotherapy-based regimen) is made by the treating physician, usually for patients with low-burden disease or for patients referred to our institute in remission when no further salvage chemotherapy is planned. Choice of which cytokine (filgrastim versus pegfilgrastim) was based on pragmatic issues such as patient preference and resource availability for multiple daily injections versus once-only injection. Patients were identified from our institutional database for stem cell mobilization, and data was collected by searching for patients scheduled for cytokine-alone mobilization. This technique captured all patients attempting cytokinealone mobilization, thus allowing analysis on an intent-to-treat basis.
Mobilization and collection regimen Filgrastim alone mobilization. Patients were injected daily with filgrastim 10 mcg/kg (rounded up to 300 mcg or 480 mg vial size or combination thereof) daily from day 1. Filgrastim was administered in the evening, and PB CD34 þ (PBCD34 þ ) cell monitoring commenced on the morning of day 4. Apheresis was commenced when the PB CD34 þ level was greater than 5 Â 10 6 /L. Daily filgrastim dosing continued each day until collection was completed.
Pegfilgrastim-alone mobilization. Patients were injected with a single dose of pegfilgrastim on day 1. PB CD34 þ cell monitoring commenced on day 4. Apheresis was commenced when the PB CD34 þ level was greater
/L. With respect to dose of pegfilgrastim, we initiated this study at a dose of 12 mg pegfilgrastim based on some preliminary evidence that 12 mg may be superior to 6 mg in the setting of cytokineonly mobilization of healthy allogeneic donors. 30 Our approach changed for the final two patients from using 12 mg to 6 mg after the emergence of data suggesting that for mobilization, 12 mg and 6 mg doses have similar efficacy. 20 
Apheresis
Apheresis was continued daily for up to 6 days or until either a successful collection (success was defined as X2 Â 10 6 CD34 þ cells/kg) was achieved, or an assessment was made that continuing apheresis in the setting of low PBCD34 þ counts (o5 Â 10 6 /L) was considered clinically futile. Autologous HPC-A collections were performed by the apheresis unit under current good manufacturing practice (cGMP) conditions using Cobe Spectra (Cobe, Denver, CO, USA) and Haemonetics MCS þ (Baxter Healthcare Corp, Deerfield, IL, USA) apheresis machines. Collection was performed until two blood volumes (Spectra, continuous processing) or 1.5 blood volumes (MCS þ -discontinuous processing) were processed. There was no significant difference in the number of blood volumes processed between the pegfilgrastim and filgrastim groups.
Flow Cytometric CD34
þ HPC Determination
Viable PB CD34 þ cell collection CD34 þ cell counts were performed using a single platform method based on the ISHAGE gating strategy using a flow cytometer (Becton Dickinson FACSCalibur, San Jose, CA, USA). Briefly, a volume of whole blood or buffy coat was incubated with 10 mL of CD45 FITC (Immunotech clone J33, Marseille, France), 10 mL of CD34 PE (Immunotech clone 581, Marseille, France) and 10 mL of 7AAD for 15 min at room temperature in the dark. Red cells were then lysed with ammonium chloride for 10 min. An equal volume of well-mixed FlowCount fluorospheres of known concentration were then added and data acquired on the flow cytometer without washing. PB CD34 þ results and collection CD34 þ results were calculated and reported as cells Â 10 6 /L and cells Â 10 6 per kg body weight, respectively.
Statistical methods
For comparison between filgrastim and pegfilgrastim, the two-sided Fishers' exact test was used for categorical variables, the exact CochranArmitage test for ordinal categorical variables and t-test for continuous variables. Continuous variables that were not normally distributed were transformed on a natural log scale to assess differences between groups. The 95% confidence interval (CI) associated with the percentage of patients with successful collection of X2 Â 10 6 CD34 þ cells/kg was calculated using an exact method based on the binomial distribution (Blyth-Still-Casella method). A log-rank (Mantel-Cox) test was used to assess time to achieving the target collection yield.
RESULTS

Patient characteristics
Patient characteristics were similar for the two cohorts (Table 1) . Over 92% of the patients were evaluable for their history of prior lines of treatment, and there were no significant differences with respect to predictors for poor mobilization such as prior exposure to alkylating agents, radiation to the marrow-bearing bone, prior fludarabine exposure (which has previously been associated with poor mobilization) [34] [35] [36] or rate of plasma cell disorders in the filgrastim group; a factor that can be associated with better stem cell collections.
The incidence of prior failed mobilization (defined as a previous attempt failing to collect X2 Â 10 6 per kg CD34 þ cells) was similar in each group. There was a suggestion that a higher proportion of patients in the filgrastim group had previously attempted mobilization (30%; n ¼ 9 versus 9%; n ¼ 2, P ¼ NS). Of the two pegfilgrastim patients with a prior mobilization attempt, both were remobilized because of insufficient cells being collected for safe delivery of SCT. Of the nine filgrastim patients undergoing a remobilization, four were because of failure of the first attempt, and five patients had elective remobilizations due to concerns regarding the age of their stored product and the likelihood of relapse and requirement for transplantation in the foreseeable future.
Mobilization success The total CD34
þ cell yield (that is, total of cells collected from each apheresis day) was equivalent for both filgrastim-and pegfilgrastim-mobilized patients (median (range) of 3.70 Â 10 6 per kg (0.09-9.30 Â 10 6 per kg) versus 4.78 Â 10 6 per kg (0.04-41.02 Â 10 6 per kg) CD34 þ cells, respectively, P ¼ 0.23) across a similar median number of aphereses (Table 2 and Figure 1 ). Successful mobilization (defined as a total HSPC collection of X2 Â 10 6 per kg CD34 þ cells) was achieved in 80% (95% CI 61-92%) of filgrastimmobilized patients in a median 3 (range: 4-6) apheresis procedures ( Table 2 ). In comparison, this was achieved in 91% (71-99%) of pegfilgrastim-mobilized patients in a median 3 (range: 1-4) apheresis procedures. There was no statistically significant difference between the groups in terms of the total HSPC collection and the percentage of patients achieving a target amount, although there was perhaps a suggestion that a slightly higher proportion of patients in the pegfilgrastim group achieved the 3 analysed targets of 2 Â 10 6 per kg, 4 Â 10 6 per kg and 5 Â 10 6 per kg CD34 þ cells (Table 2) .
Although there appeared to be a trend towards fewer days of collection needed to achieve the CD34 þ cell target of 2 Â 10 6 per kg in the pegfilgrastim group, and a trend towards a higher proportion of pegfilgrastim patients achieving the target of 2 Â 10 6 per kg CD34 þ cells within one apheresis, these differences were not statistically significant (P ¼ 0.368; Figure 2 ).
There was a trend (P ¼ 0.08) towards a higher proportion of patients mobilized with pegfilgrastim reaching the threshold for apheresis by day 4 post treatment; however, this was not statistically significant. Similarly, there was a trend (P ¼ 0.06, calculated on transformed data due to non-normal distribution) towards a higher PB CD34 þ cell count on the first day of apheresis in patients mobilized with pegfilgrastim-alone (Figure 3) . Analysis of transformed data did not show a statistically significant difference for day 3 PBCD34 þ counts.
Adverse events One patient experienced asymptomatic hyperleukocytosis (defined as WCC 4100 Â 10 9 /L). This patient was mobilized with 12 mg pegfilgrastim. He had POEMS syndrome. His WCC was elevated to 199.4 Â 10 9 /L on day 4. On day 5, his WCC had increased to peak at 230 Â 10 9 /L. He underwent apheresis twice on day 5 in an attempt to reduce his circulating cells. After a total For non-normally distributed data, geometric mean, 95% confidence intervals, and P-value computed on transformed data.
Cytokine mobilization: pegfilgrastim equivalent to filgrastim KE Herbert et al of 4 apheresis procedures, his total collection was successful at 4.31 Â 10 6 per kg CD34 þ cells (Figure 4 ). He fully recovered to a normal WCC within 1 week of day 4. There were no other significant grade 3 or 4 toxicities reported.
DISCUSSION
Cytokine-alone mobilization is preferred over chemotherapycytokine mobilization in clinical contexts where no further debulking chemotherapy is needed, for example, patients in remission from their underlying disease, or where there is a high priority to minimize the toxic effects of chemotherapy both acutely and in terms of the risk of second malignancies. It also has the added advantage of predictable kinetics, making scheduling of patients for apheresis easier. This can be critical for busy apheresis units where scheduling and staffing issues are a priority. Indeed, much of the data regarding cytokine-alone mobilization using filgrastim comes from the healthy allogeneic donor setting where these requirements are paramount.
Pegylated filgrastim for cytokine-only mobilization has the theoretical advantage of improved kinetics if it is able to smooth out the peaks and troughs of PB CD34 þ cells that are seen in filgrastim dosing, 37, 38 plus the potential for increased acceptability to the patient given its single-dose administration.
To date, there have been few published reports on the efficacy of pegfilgrastim-alone as a mobilizing agent, and even fewer comparing pegfilgrastim-alone to filgrastim-alone in the autologous mobilization setting (summarized in Table 3 ). An Amgensponsored clinical trial, comparing filgrastim to either 6 or 12 mg of pegfilgrastim in patients with lymphoma, was terminated early because fewer than 50% of patients receiving pegfilgrastim achieved above 2 Â 10 9 per kg CD34 þ cells. This trial was never published, and the available analysis is notable for an unusually low mobilization success rate (63% overall) suggesting that the population studied was somewhat atypical. Numbers were too small for a powered statistical analysis, and no information is available regarding patient characteristics that may have contributed to risk for poor mobilization. Of interest, in the Amgen study, patients did not commence collection until day 5, 1 day later than our strategy, which may have impacted adversely on the cumulative yield as PB CD34 þ cell counts on day 4 and day 5 are equivalent ( Figure 3) .
In the allogeneic setting, pegfilgrastim is as effective as filgrastim and indeed, there is evidence that 12 mg may be superior in terms of mobilization efficacy with one study demonstrating that the majority of donors treated with 12 mg pegfilgrastim (n ¼ 13) collected sufficient HSPC in one apheresis, as opposed to donors treated with 6 mg pegfilgrastim (n ¼ 5) who required at least two apheresis procedures. 30 Kroschinsky et al.
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demonstrated efficacy of pegfilgrastim in CD34 þ cell mobilization in 25 healthy donors, noting 100% success with 80% donors achieving their target yield in just one apheresis.
In the autologous setting, there is only one other published study of pegfilgrastim for cytokine-alone mobilization in haematological malignancy in which a parallel group received filgrastim alone; however, this was not a true comparative study. Hosing et al. 31 demonstrated the efficacy of 12 mg pegfilgrastim-alone for mobilization in 19 patients with myeloma, and included data from 8 patients mobilized with filgrastim-alone, because they were not eligible for pegfilgrastim, mostly because of enlarged spleen at baseline. The numbers in this study were, however, too small to draw any comparisons between these two approaches in terms of mobilization efficacy. Another study in adult solid tumour patients (n ¼ 61) compared CD34 þ counts after different doses of pegfilgrastim-alone to filgrastim and demonstrated equivalence between filgrastim and pegfilgrastim 12 mg, with a slight superiority of pegfilgrastim 18 mg; however, these results were only of PBCD34 þ kinetics, as apheresis was not performed on these patients.
In this study, we demonstrate for the first time the equivalence in both predictable mobilization kinetics and CD34 þ apheresis yield efficacy of pegfilgrastim compared with filgrastim for cytokine-alone mobilization. Results of CD34 þ yield, number of days of apheresis, days to achieve target yield of X2 Â 10 6 per kg CD34 þ cells were similar in a group of pegfilgrastim-alone mobilized patients compared with a well-matched group of patients mobilized with filgrastim-alone. Although numbers in this analysis are small, our data provides evidence that pegfilgrastimalone can be a valid mobilization option for selected patients, where there is a paucity of other published data on this approach for mobilization. With respect to the dose of pegfilgrastim used, it has previously been demonstrated in chemotherapy mobilization that 6 mg of pegfilgrastim is as effective as 12 mg to mobilize autologous HSPC following chemotherapy. 20 In the abovementioned (unpublished) Amgen trial, numbers were also too small to compare efficacy between 6 mg versus 12 mg pegfilgrastim for cytokine-alone mobilization, so this question remains unanswered in the literature. Our isolated case of hyperleukocytosis following 12 mg of pegfilgrastim provides at least anecdotal support for the use of the more conservative 6 mg pegfilgrastim dose when used without chemotherapy. Nonetheless, in this case of hyperleukocytosis, although the white cell count was high, the circulating PB CD34 þ cell count and daily yields were only moderate.
We conclude that pegfilgrastim-alone is an effective mobilizing agent with predictable kinetics, similar to that observed with filgrastim. Larger studies comparing 6 mg pegfilgrastim to filgrastim would determine if some of observations suggesting superiority of pegfilgrastim are borne out. Finally, this regimen would be particularly suitable in the allogeneic and paediatric setting due to its ease of administration and lack of the requirement for mobilizing chemotherapy. Cytokine mobilization: pegfilgrastim equivalent to filgrastim KE Herbert et al
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